About PaxVax
PaxVax is a company based in San Diego (United States) founded in 2007 was acquired by Emergent BioSolutions in August 2018.. PaxVax has raised $211.78 million across 9 funding rounds from investors including Emergent BioSolutions, Ignition Capital and Cerberus Capital Management. The company has 138 employees as of December 31, 2018. PaxVax operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, HOOKIPA Pharma and Freeline, among others.
- Headquarter San Diego, United States
- Employees 138 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Paxvax, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$211.78 M (USD)
in 9 rounds
-
Latest Funding Round
$105 M (USD), Series C
Dec 08, 2015
-
Investors
Emergent BioSolutions
& 5 more
-
Employee Count
138
as on Dec 31, 2018
-
Acquired by
Emergent BioSolutions
(Aug 09, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PaxVax
PaxVax has successfully raised a total of $211.78M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $105 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series C — $105.0M
-
First Round
First Round
(06 Nov 2009)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2015 | Amount | Series C - PaxVax | Valuation |
investors |
|
| Aug, 2014 | Amount | Series B - PaxVax | Valuation |
investors |
|
| Jul, 2014 | Amount | Debt – Conventional - PaxVax | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PaxVax
PaxVax has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Emergent BioSolutions, Ignition Capital and Cerberus Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Private equity and debt firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Impact investments are managed through a diversified family office portfolio.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PaxVax
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PaxVax
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Paxvax Comparisons
Competitors of PaxVax
PaxVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, HOOKIPA Pharma and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Allergen immunotherapies for respiratory allergies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Paxvax
Frequently Asked Questions about PaxVax
When was PaxVax founded?
PaxVax was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Where is PaxVax located?
PaxVax is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is PaxVax a funded company?
PaxVax is a funded company, having raised a total of $211.78M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $50M, raised on Nov 06, 2009.
How many employees does PaxVax have?
As of Dec 31, 2018, the latest employee count at PaxVax is 138.
What does PaxVax do?
PaxVax was founded in 2007 in San Diego, United States, within the biotechnology sector focused on infectious disease prevention. Vaccine candidates are developed and commercialized, including PXVX0200 as a single-dose oral cholera vaccine, PXVX0103 for avian influenza, and an anthrax protection candidate. Ad4-env Clade C is advanced as an HIV vaccine component, while Vivotif is commercialized for typhoid fever. Operations emphasize oral administration technologies.
Who are the top competitors of PaxVax?
PaxVax's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
Who are PaxVax's investors?
PaxVax has 6 investors. Key investors include Emergent BioSolutions, Ignition Capital, Cerberus Capital Management, BioPharma Funds, and Blue Haven Initiative.